General description
Nifurtimox acts as a hypoxia-activated cytotoxin, which specifically kills clonogenic tumor cells under hypoxic conditions. It is used to treat Chagas disease and African trypanosomiasis. Nifurtimox inhibits neuroblastoma and medulloblastoma cell growth.
Application
Nifurtimox has been used in drug treatment in culture media.
Biochem/physiol Actions
Nifurtimox is a nitrofurane derivative used to treat diseases caused by trypanosomes.
Nifurtimox is a nitrofurane derivative used to treat diseases caused by trypanosomes. Nifurtimox was discovered empirically and its mechanism of action is unclear. It is believed that nifurtimox exerts its biological activity through the bioreduction of the nitro-group to a nitro-anion radical which undergoes redox-cycling with molecular oxygen.
Features and Benefits
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | yellow to orange |
| solubility | DMSO: ≥13 mg/mL |
| originator | Bayer |
| storage temp. | room temp |
| SMILES string | CC1CS(=O)(=O)CCN1\N=C\c2ccc(o2)[N+]([O-])=O |
| InChI | 1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+ |
| InChI key | ARFHIAQFJWUCFH-IZZDOVSWSA-N |
